The event will take place Thursday, September 8, 2011, in downtown Chicago.
Source: The American Herbal Products Association
The American Herbal Products Association (AHPA) is pleased to announce the "AHPA Congress on New Dietary Ingredients (NDIs): Crafting an Industry Response & Filing Successful Notifications," a one-day intensive to help herbal and dietary supplement companies take the next step in responding to the Food and Drug Administration's (FDA) draft guidance on NDIs and to develop and submit NDI notifications for numerous product categories.
This highly interactive educational gathering will take place Thursday, September 8, 2011, from 8:30 a.m. - 5:30 p.m., at the Mesirow Financial corporate headquarters in downtown Chicago.
"Based on member and industry feedback, there are still numerous questions about FDA's NDI guidance and the industry comment process," said AHPA President Michael McGuffin. "Additionally, there is a clear need for hands-on instruction on how to file NDI notifications. This AHPA event will fill these information voids to benefit the entire industry."
The AHPA Congress on NDIs will sift through the clutter, the hype and unanswered questions on NDIs to provide clarity and help industry companies answer the following questions:
The AHPA Congress on NDIs is geared to all companies that rely on new products and product innovation and whose products fall under the regulatory framework created by the Dietary Supplement Health and Education Act (DSHEA).
Click HERE to register.
The AHPA Congress on NDIs is generously supported by:
Session 1: Crafting an Industry Response to the NDI Guidance
McGuffin--widely considered to be one of the industry's leading experts on NDIs--will moderate this town-hall-style discussion on the development of industry's comments regarding the draft NDI guidance. Participants will have the opportunity to voice their concerns and positions and have them discussed among a panel of attorneys recognized as NDI experts, including:
Session 2: Filing Successful NDI Notifications
The afternoon session features preeminent companies with real-world experience in creating high-caliber, successful NDI submissions. The presenters will deliver practical, hands-on information and advice on the necessary steps needed to develop and submit NDI notifications for numerous product categories.
Hear from:
The Program - Thursday, September 8, 2011
8 - 9 a.m. - Registration, Continental Breakfast, Networking
9 a.m. - 12:30 p.m. - Session 1
12:30 - 1:30 p.m. - Lunch, provided by Grifcon Enterprises
1:30 - 5:30 p.m. - Session 2
5:30 p.m. - Adjournment
Event Registration
Attendance is limited to 100 participants. Early registration is suggested.Click HERE to register.
Conference Location & Lodging Information
The AHPA NDI Congress will be held at the Mesirow Financial corporate headquarters, 353 North Clark St., Chicago, IL 60654.
A limited number of rooms have been reserved at the Residence Inn Chicago Downtown/River North for the night of September 7 at a special rate of $159 on a first-come, first-served basis. For reservations at the discounted price, contact Liz Rejniak, Gray's Travel Management, via phone: 800.966.8728, or email. Mention the "AHPA-Mesirow Congress" to receive this discount. Please do not contact the hotel directly.
Other nearby hotels:
Westin Chicago River North
312.744.1900
SpringHill Suites Chicago
312.644.4071
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.